Maria Zannes - 01 Oct 2023 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Role
President, CEO, Director
Signature
/s/ Maria Zannes
Issuer symbol
BIAF
Transactions as of
01 Oct 2023
Net transactions value
+$37,498
Form type
4
Filing time
24 Jan 2024, 20:52:47 UTC
Previous filing
06 Jul 2023
Next filing
02 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIAF Common Stock Award $18,750 +11,867 +10% $1.58 128,105 01 Oct 2023 Direct F1
transaction BIAF Common Stock Award $18,749 +12,668 +9.9% $1.48 140,773 01 Jan 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant from Issuer to Ms. Zannes of 11,867 restricted shares of Common Stock, on October 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.
F2 Represents a grant from the Issuer to Ms. Zannes of 12,668 restricted shares of Common Stock, on January 1, 2024 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.

Remarks:

Exhibit List Exhibit 24.1 - Power of Attorney (Maria Zannes)